Serbia vs United Arab Emirates: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Serbia
91.0%
in 2025
United Arab Emirates
91.0%
in 2025
Serbia rank
61st
United Arab Emirates rank
61st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Serbia
- United Arab Emirates
How they compare
Serbia currently reports 91.0% against 91.0% in United Arab Emirates, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was United Arab Emirates ahead.
Serbia ranks 61st and United Arab Emirates ranks 61st of 194 countries.
United Arab Emirates has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Serbia | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 15.9% | 97.4% | 81.5% | United Arab Emirates |
| 2020s | 87.5% | 92.2% | 4.7% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Serbia or United Arab Emirates?
- Serbia, at 91.0% against 91.0% in United Arab Emirates as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Serbia and United Arab Emirates?
- 0.0%, with Serbia ahead.
- How many years of comparable data are there for Serbia and United Arab Emirates?
- 18 years are reported by both, from 2008 to 2025.
- How do Serbia and United Arab Emirates rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Serbia ranks 61st and United Arab Emirates ranks 61st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.